Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026Five additional Phase 3 studies of azetukalner continue to ...
Investor's Business Daily on MSN
Xenon Pharmaceuticals stock scores RS rating upgrade
Xenon Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating ...
Xenon Pharmaceuticals is developing a drug for the most common type of seizure experienced by people with epilepsy. Here's ...
nasdaq composite visibility underscores the company’s presence within broader healthcare and innovation-driven market discussions ...
Xenon (NASDAQ:XENE) draws attention in Nasdaq Futures after unusual put option spike and active institutional shifts.
This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and ...
– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD studies ...
In the third quarter, Xenon met analyst expectations with a loss of $1.15 per share and zero revenue. The company has delivered consistent execution on its clinical timeline, with multiple Phase 3 ...
VANCOUVER, British Columbia and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results